Vaxcyte Inc.is a biopharmaceutical company develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate and complex antigen-based vaccines. Vaxcyte Inc.is based in Foster City, California.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-463.93M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.32 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -17.12% |
| Return on Assets (Trailing 12 Months) | -16.26% |
| Current Ratio (Most Recent Fiscal Quarter) | 17.70 |
| Quick Ratio (Most Recent Fiscal Quarter) | 17.70 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $24.81 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.04 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.80 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.99 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 129.00M |
| Free Float | 125.00M |
| Market Capitalization | $4.23B |
| Average Volume (Last 20 Days) | 2.40M |
| Beta (Past 60 Months) | 1.27 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 96.78% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |